912 related articles for article (PubMed ID: 11694790)
1. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
2. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
3. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
Wan D; Zhang Y; Yu Q; Li F; Zhuo J
Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
Xu J; Li F; Chang F
Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
[TBL] [Abstract][Full Text] [Related]
7. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
8. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
[No Abstract] [Full Text] [Related]
9. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F
J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900
[TBL] [Abstract][Full Text] [Related]
10. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
11. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
12. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
[TBL] [Abstract][Full Text] [Related]
13. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor.
Xu S; Wei B; Zhang H; Qing M; Bu H
Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952
[TBL] [Abstract][Full Text] [Related]
14. Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival.
Tot T
Ann Surg Oncol; 2015 Aug; 22(8):2532-9. PubMed ID: 25582746
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.
Visscher DW; Frost MH; Hartmann LC; Frank RD; Vierkant RA; McCullough AE; Winham SJ; Vachon CM; Ghosh K; Brandt KR; Farrell AM; Tarabishy Y; Hieken TJ; Haddad TC; Kraft RA; Radisky DC; Degnim AC
Cancer; 2016 Feb; 122(3):378-85. PubMed ID: 26512815
[TBL] [Abstract][Full Text] [Related]
16. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
17. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors of breast cancer].
Tang P; Wei B; Yang WJ; Liu YS; Bu H
Zhonghua Bing Li Xue Za Zhi; 2011 Feb; 40(2):73-6. PubMed ID: 21426799
[No Abstract] [Full Text] [Related]
19. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Arpino G; Bardou VJ; Clark GM; Elledge RM
Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
[TBL] [Abstract][Full Text] [Related]
20. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C
Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
